Dataset Information


Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity.

ABSTRACT: Hsp90 is an essential molecular chaperone that is also a novel anti-cancer drug target. There is growing interest in developing new drugs that modulate Hsp90 activity.Using a virtual screening approach, 4-hydroxytamoxifen, the active metabolite of the anti-estrogen drug tamoxifen, was identified as a putative Hsp90 ligand. Surprisingly, while all drugs targeting Hsp90 inhibit the chaperone ATPase activity, it was found experimentally that 4-hydroxytamoxifen and tamoxifen enhance rather than inhibit Hsp90 ATPase.Hence, tamoxifen and its metabolite are the first members of a new pharmacological class of Hsp90 activators.

PROVIDER: S-EPMC2848575 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC5364056 | BioStudies
2018-01-01 | S-EPMC5866846 | BioStudies
| S-EPMC5921262 | BioStudies
| S-EPMC7558379 | BioStudies
| S-EPMC3711775 | BioStudies
| S-EPMC4699796 | BioStudies
| S-EPMC6921430 | BioStudies
| S-EPMC5071318 | BioStudies
1993-01-01 | S-EPMC1134159 | BioStudies
2003-01-01 | S-EPMC1223614 | BioStudies